Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Mallinckrodt
Merck
Dow
McKesson

Last Updated: January 27, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Gimeracil


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Gimeracil?

Gimeracil is an investigational drug.

There have been 76 clinical trials for Gimeracil. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.

The most common disease conditions in clinical trials are Stomach Neoplasms, Pancreatic Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Fudan University, Taiho Oncology, Inc., and Yonsei University.

There are five hundred and fifty-five US patents protecting this investigational drug and five international patents.

Recent Clinical Trials for Gimeracil
TitleSponsorPhase
Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerSuzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2/Phase 3
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction CancOno Pharmaceutical Co. LtdPhase 3
HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric JunctionXuefei.WangPhase 2

See all Gimeracil clinical trials

Clinical Trial Summary for Gimeracil

Top disease conditions for Gimeracil
Top clinical trial sponsors for Gimeracil

See all Gimeracil clinical trials

US Patents for Gimeracil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gimeracil ⤷  Try it Free Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) ⤷  Try it Free
Gimeracil ⤷  Try it Free Aryl-cyanoguanidine compounds Bayer Pharma Aktiengesellschaft (Berlin, DE) ⤷  Try it Free
Gimeracil ⤷  Try it Free Metal-salen complex compound, local anesthetic and antineoplastic drug IHI Corporation (Tokyo, JP) Ishikawa; Yoshihiro (Tokyo, JP) ⤷  Try it Free
Gimeracil ⤷  Try it Free Multimodal silica-based nanoparticles ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Gimeracil

Drugname Country Document Number Estimated Expiration Related US Patent
Gimeracil Argentina AR098961 2033-12-23 ⤷  Try it Free
Gimeracil Australia AU2014372833 2033-12-23 ⤷  Try it Free
Gimeracil Canada CA2934617 2033-12-23 ⤷  Try it Free
Gimeracil China CN106163568 2033-12-23 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Mallinckrodt
Merck
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.